Prediabetes means blood glucose is above normal but below the diabetes range and increases the risk of type 2 diabetes. NIH's NIDDK explains that nutrition, activity and weight management can help address risk. Medication choices depend on an individualized medical assessment.
What Is Prediabetes?
Prediabetes is diagnosed when blood sugar levels are higher than normal but not yet high enough for a type 2 diabetes diagnosis. The standard diagnostic criteria are:
How GLP-1 Medications Address Prediabetes
GLP-1 medications address prediabetes through multiple mechanisms simultaneously:
- Weight Management
NIDDK describes weight management and physical activity as parts of reducing diabetes risk. A trial average cannot forecast an individual's weight or glucose response.
- Glucose Measures
Research published in Diabetes Care reported improvements in glucose measures during semaglutide treatment among STEP participants with prediabetes. This does not establish the same benefit for every preparation or patient.
- Reduced Post-Meal Blood Sugar Spikes
By slowing gastric emptying, GLP-1 medications reduce the rate of glucose absorption after meals — flattening the blood sugar response that is particularly elevated in prediabetes.
- Enhanced Insulin Secretion
GLP-1 medications stimulate insulin secretion in a glucose-dependent manner — meaning the pancreas releases more insulin when blood sugar is high, and less when it is normal. This directly corrects the impaired insulin response characteristic of prediabetes.
What the Clinical Evidence Shows
Research published in Diabetes Care by Perreault and colleagues reported that more STEP participants with baseline prediabetes had normal-range glucose at 68 weeks with semaglutide 2.4 mg plus lifestyle intervention than with placebo. Some analyses were post hoc, and glucose normalization while on treatment is not proof of a permanent cure.
Research published in the New England Journal of Medicine by Lincoff and colleagues reported fewer major cardiovascular events with semaglutide in SELECT participants aged at least 45 who had established cardiovascular disease and overweight or obesity, without diabetes. It does not establish the same benefit for every GLP-1 medicine or every patient with prediabetes.
These findings support a discussion of treatment options in the populations studied. They do not establish GLP-1 medications as the best diabetes-prevention approach for every patient or replace individualized advice.
Does Having Prediabetes Help You Qualify?
Prediabetes is relevant to a provider's review of metabolic health. The approved products have weight-management indications based on obesity or overweight with a weight-related condition, but a prediabetes diagnosis alone does not guarantee eligibility. Your provider must apply the specific product's current criteria, contraindications and your complete history.